HLS Therapeutics Inc.
HLTRF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $57 | $63 | $61 | $60 |
| % Growth | -10.2% | 2.6% | 2.4% | – |
| Cost of Goods Sold | $9 | $8 | $5 | $4 |
| Gross Profit | $48 | $55 | $56 | $56 |
| % Margin | 84.1% | 87.9% | 91.9% | 93.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $10 | $8 | $18 | $17 |
| SG&A Expenses | $27 | $28 | $36 | $32 |
| Sales & Mktg Exp. | $17 | $20 | $18 | $15 |
| Other Operating Expenses | $28 | $27 | $0 | $0 |
| Operating Expenses | $55 | $55 | $70 | $62 |
| Operating Income | -$8 | -$10 | -$13 | -$6 |
| % Margin | -13.6% | -16.4% | -21.9% | -10.5% |
| Other Income/Exp. Net | -$8 | -$17 | -$10 | -$6 |
| Pre-Tax Income | -$16 | -$28 | -$24 | -$12 |
| Tax Expense | $4 | -$0 | -$0 | $1 |
| Net Income | -$20 | -$28 | -$24 | -$13 |
| % Margin | -34.7% | -43.6% | -38.4% | -21.9% |
| EPS | -0.62 | -0.85 | -0.73 | -0.41 |
| % Growth | 27.1% | -16.4% | -78% | – |
| EPS Diluted | -0.62 | -0.85 | -0.73 | -0.41 |
| Weighted Avg Shares Out | 32 | 32 | 32 | 32 |
| Weighted Avg Shares Out Dil | 32 | 32 | 32 | 32 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $10 | $9 | $7 | $7 |
| Depreciation & Amortization | $23 | $32 | $33 | $30 |
| EBITDA | $17 | $13 | $17 | $25 |
| % Margin | 30.4% | 20.4% | 28.1% | 42% |